Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Zerbaxa (ceftolozane/tazobactam) is indicated in combination with metronidazole for patients 18 years or older for the treatment of complicated intra-abdominal infections (cIAI) caused by designated susceptible microorganisms. It is also indicated in adult and pediatric patients (birth to less than 18 years old) for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by designated susceptible microorganisms, and in adult patients 18 years and older for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) caused by designated susceptible microorganisms.
• This summary is based on the review of 17 systematic review(s)/meta-analysis(es). ^[1-17]
• Clinical Cure and Microbiological Response in PA Infections: Ceftolozane/tazobactam (TOL-TAZ) showed no significant difference compared to other regimens, including ceftazidime-avibactam, imipenem-cilastatin-relebactam, and cefiderocol, with RRs of 1.04 (95% CI: 0.94-1.15) and 0.97 (95% CI: 0.81-1.17).
• Complicated Intra-Abdominal Infections (cIAIs): TOL-TAZ demonstrated similar clinical cure rates compared to carbapenems in clinically evaluable (93.6% vs. 93.7%), microbiologically evaluable (93.0% vs. 94.5%), and modified intention-to-treat (85.9% vs. 87.7%) populations.
• Complicated Urinary Tract Infections (cUTIs): TOL-TAZ exhibited higher clinical cure (92%) and microbiological eradication (83%) rates than piperacillin/tazobactam (78% and 63%, respectively).
• Gram-Negative Bacterial Infections: TOL-TAZ showed advantages in clinical cure (OR, 1.62; 95% CI, 1.05-2.51) and microbiological eradication (OR, 1.43; 95% CI, 1.19-1.71), particularly in treating Pseudomonas aeruginosa infections.
• TOL-TAZ exhibited similar rates of adverse events, including treatment-emergent adverse events and serious adverse events, compared to other antimicrobials, with no significant differences observed across multiple studies.
• There was no increased risk of Clostridium difficile infection associated with TOL-TAZ, and it showed a lower risk of acute kidney injury compared to polymyxin/aminoglycosides.
• TOL-TAZ demonstrated a favorable safety profile in newborns, infants, and children when treating multidrug-resistant Gram-negative infections, with no specific adverse events reported.
• There is no population types or subgroups information available in the reviewed studies.